Back to Browse Journals » Biologics: Targets and Therapy » Volume 2 » Issue 2

Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications

Authors Paul N Knoebl

Published 6 June 2008 Volume 2008:2(2) Pages 285—296


Paul N Knoebl

Department of Medicine 1, Division Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria

Abstract: The protein C pathway has an important function in regulating and modulating blood coagulation and ensuring patency of the microcirculation. Protein C deficiency leads to macro- and microvascular thrombosis. Congenital severe protein C deficiency is a life-threatening state with neonatal purpura fulminans and pronounced coagulopathy. Patients with heterozygous protein C deficiency have an increased risk for thromboembolic events or experience coumarin-induced skin necrosis during initiation of coumarin therapy. Replacement with protein C concentrates is an established therapy of congenital protein C deficiency, resulting in rapid resolving of coagulopathy and thrombosis without reasonable side effects. This article summarizes the current knowledge on protein C replacement therapy in congenital protein C deficiency.

Keywords: protein C, deficiency, replacement therapy, purpura fulminans, coagulopathy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Electrostatic self-assembly of multilayer copolymeric membranes on the surface of porous tantalum implants for sustained release of doxorubicin

Guo X, Chen M, Feng W, Liang J, Zhao H, Tian L, Chao H, Zou X

International Journal of Nanomedicine 2011, 6:3057-3064

Published Date: 28 November 2011

Use of a decoy peptide to purify p21 activated kinase-1 in cardiac muscle and identification of ceramide-related activation

Yunbo Ke, R John Solaro

Biologics: Targets and Therapy 2008, 2:903-909

Published Date: 5 December 2008

Adalimumab for the treatment of Crohn’s disease

Andrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi Porro

Biologics: Targets and Therapy 2008, 2:763-777

Published Date: 5 December 2008

Novel microtubule-targeting agents – the epothilones

Kit L Cheng, Thomas Bradley, Daniel R Budman

Biologics: Targets and Therapy 2008, 2:789-811

Published Date: 5 December 2008

Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside

Ana Villegas, Fernando A Gonzalez, Leopoldo Llorente, Santiago Redondo

Biologics: Targets and Therapy 2008, 2:397-407

Published Date: 12 September 2008

Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

Peter J O’Brien, Rajeev Ramanathan, Jonathan M Yingling, Jose Baselga, Mace L Rothenberg, et al

Biologics: Targets and Therapy 2008, 2:563-569

Published Date: 12 September 2008

Novel targets for immunotherapy in glomerulonephritis

Mary H Foster

Biologics: Targets and Therapy 2008, 2:531-545

Published Date: 12 September 2008

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias

Aldo M Roccaro, Irene M Ghobrial, Simona Blotta, Steven P Treon, Michele Malagola, et al

Biologics: Targets and Therapy 2008, 2:419-431

Published Date: 12 September 2008

New treatment options in the management of IBD – focus on colony stimulating factors

Josué Barahona-Garrido, Jesús K Yamamoto-Furusho

Biologics: Targets and Therapy 2008, 2:501-504

Published Date: 12 September 2008

Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance

Jennifer S Carew, Steffan T Nawrocki, Francis J Giles, John L Cleveland

Biologics: Targets and Therapy 2008, 2:201-204

Published Date: 6 June 2008